-
公开(公告)号：US09956184B2
公开(公告)日：2018-05-01
申请号：US15449124
申请日：2017-03-03
申请人： GW Pharma Limited
发明人： Geoffrey Guy , Stephen Wright , Alice Mead , Orrin Devinsky
IPC分类号： A61K31/05 , A61K31/5513
CPC分类号： A61K31/05 , A61K9/0053 , A61K9/08 , A61K31/165 , A61K31/19 , A61K31/195 , A61K31/197 , A61K31/20 , A61K31/27 , A61K31/35 , A61K31/352 , A61K31/36 , A61K31/4015 , A61K31/4166 , A61K31/423 , A61K31/444 , A61K31/496 , A61K31/515 , A61K31/53 , A61K31/55 , A61K31/551 , A61K31/5513 , A61K31/5517 , A61K31/7048 , A61K36/185 , A61K45/06 , A61K47/10 , A61K47/26 , A61K47/44 , A61K2300/00
摘要： The present disclosure relates to the use of cannabidiol (CBD) for the reduction of total convulsive seizure frequency in the treatment of “treatment-resistant epilepsy” (TRE). In particular, the disclosure relates to the use of CBD of treating TRE when the TRE is Dravet syndrome; myoclonic absence seizures or febrile infection related epilepsy syndrome (FIRES). The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
-
公开(公告)号：US20180042975A1
公开(公告)日：2018-02-15
申请号：US15620435
申请日：2017-06-12
发明人： Daniela Parolaro , Paola Massi , Angelo Antonio Izzo , Francesca Borrelli , Gabriella Aviello , Vincenzo Di Marzo , Luciano De Petrocellis , Aniello Schiano Moriello , Alessia Ligresti , Ruth Alexandra Ross , Lesley Ann Ford , Sharon Anavi-Goffer , Manuel Guzman , Guillermo Velasco , Mar Lorente , Sofia Torres , Tetsuro Kikuchi , Geoffrey Guy , Colin Stott , Stephen Wright , Alan Sutton , David Potter , Etienne De Meijer
IPC分类号： A61K36/185 , A61K31/01 , A61K31/05 , A61K45/06 , A61K31/337 , A61K31/352 , A61K31/495 , A61K31/015 , A61K31/192
CPC分类号： A61K36/185 , A61K31/01 , A61K31/015 , A61K31/05 , A61K31/192 , A61K31/337 , A61K31/352 , A61K31/495 , A61K45/06 , A61K2300/00
摘要： This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
-
公开(公告)号：US20170273913A1
公开(公告)日：2017-09-28
申请号：US15346844
申请日：2016-11-09
发明人： Benjamin Whalley , Gary Stephens , Claire Williams , Geoffrey Guy , Stephen Wright , Tetsuro Kikuchi
IPC分类号： A61K31/05 , A61K31/352
CPC分类号： A61K31/05 , A61K31/352
摘要： This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
-
公开(公告)号：US20170239193A1
公开(公告)日：2017-08-24
申请号：US15519244
申请日：2015-10-14
申请人： GW Pharma Limited
发明人： Geoffrey Guy , Stephen Wright , Alice Mead , Orrin Devinsky
IPC分类号： A61K31/05
CPC分类号： A61K31/05 , A61K31/352 , A61K36/185
摘要： The present disclosure relates to the use of cannabidiol (CBD) for the treatment of of nocturnal snoring. In particular the CBD appears particularly effective in treating nocturnal snoring in children and young adults with epilepsy the disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
-
公开(公告)号：US09675654B2
公开(公告)日：2017-06-13
申请号：US14260876
申请日：2014-04-24
发明人： Daniela Parolaro , Paola Massi , Angelo Antonio Izzo , Francesca Borrelli , Gabriella Aviello , Vincenzo Di Marzo , Luciano De Petrocellis , Aniello Schiano Moriello , Alessia Ligresti , Ruth Alexandra Ross , Lesley Ann Ford , Sharon Anavi-Goffer , Manuel Guzman , Guillermo Velasco , Mar Lorente , Sofia Torres , Tetsuro Kikuchi , Geoffrey Guy , Colin Stott , Stephen Wright , Alan Sutton , David Potter , Etienne De Meijer
IPC分类号： A01N65/00 , A61K36/185 , A61K31/05 , A61K31/192 , A61K31/337 , A61K31/352 , A61K45/06 , A61K31/01 , A61K31/015 , A61K31/495
CPC分类号： A61K36/185 , A61K31/01 , A61K31/015 , A61K31/05 , A61K31/192 , A61K31/337 , A61K31/352 , A61K31/495 , A61K45/06 , A61K2300/00
摘要： This invention relates to the use of phytocannabinoids, either in an isolated form or in the form of a botanical drug substance (BDS) in the treatment of cancer. Preferably the cancer to be treated is cancer of the prostate, cancer of the breast or cancer of the colon.
-
公开(公告)号：US20160166514A1
公开(公告)日：2016-06-16
申请号：US14881954
申请日：2015-10-13
申请人： GW Pharma Limited
发明人： Geoffrey Guy , Stephen Wright , Alice Mead , Elizabeth Thiele
CPC分类号： A61K31/05 , A61K9/0095 , A61K31/352 , A61K36/185 , A61K45/06 , A61K2300/00
摘要： The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
摘要翻译： 本公开涉及大麻二醇（CBD）用于治疗结节性硬化综合征（TSC）的用途。 特别是TSC是耐药性的，其特征在于全身性发作或局部发作伴有损伤。 本公开还涉及CBD与一种或多种抗癫痫药（AED）的组合的用途。
-
17.发明申请SYNERGISTIC THERAPIES OF CANNABIDIOL WITH HYPOTHERMIA FOR NEUROPROTECTION 审中-公开CANNABIDIOL与神经保护用HYPOTHERMIA的协同治疗公开(公告)号：US20150148872A1
公开(公告)日：2015-05-28
申请号：US14405950
申请日：2013-06-10
申请人： GW Pharma Limited
发明人： Jose Martinez-Orgado , Geoffrey Guy
IPC分类号： A61K31/05 , A61F7/00 , A61K36/185
CPC分类号： A61K31/05 , A61F7/00 , A61F7/02 , A61F2007/0056 , A61K36/185 , A61K2300/00
摘要： The present invention relates to the combination of the phytocannabinoid cannabidiol with therapeutic hypothermia for use in the treatment of neuroprotection or astroprotection.
摘要翻译： 本发明涉及植物大麻素大麻二醇与用于治疗神经保护或三维保护的治疗性低温的组合。
-
公开(公告)号：US20210059959A1
公开(公告)日：2021-03-04
申请号：US16845204
申请日：2020-04-10
申请人： GW Pharma Limited
发明人： Philip ROBSON , Geoffrey Guy , Stephen Wright , Emma Cheetham , Dominic Schiller
IPC分类号： A61K31/05 , A61K31/496 , A61K31/40 , A61K31/519 , A61K31/5513 , A61K31/554 , A61P25/18 , A61K31/551
摘要： This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat both positive and negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in combination with olanzapine to treat negative symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat anhedonia/asociality in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat avolition/apathy in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy to treat disturbance of attention in mental disorders such as schizophrenia and related disorders; or as a monotherapy or as an adjunct therapy to treat one or more distinct sub-domains of negative symptoms selected from: i) avolition/apathy; ii) anhedonia/asociality and iii) disturbance of attention; or as an adjunct therapy to treat cognitive symptoms, particularly working memory, motor speed and executive function in mental disorders such as schizophrenia and related disorders. There may additionally be provided compositions comprising CBD in combination with one or more antipsychotics such as olanzapine and quetiapine. In particular the invention relates to the treatment of schizophrenia or related psychotic disorders, more particularly still those which are considered to be treatment resistant.
-
公开(公告)号：US20190247324A1
公开(公告)日：2019-08-15
申请号：US16149983
申请日：2018-10-02
申请人： GW Pharma Limited
发明人： Benjamin Whalley , Gary Stephens , Claire Williams , Geoffrey Guy , Stephen Wright , Tetsuro Kikuchi
IPC分类号： A61K31/05 , A61K31/352
CPC分类号： A61K31/05 , A61K31/352
摘要： This invention relates to the use of one or more cannabinoids in the treatment of epilepsy and more particularly to the use of one or a combination of cannabinoids in the treatment of generalized or partial seizure. In one embodiment it relates to the use of the cannabinoid THCV, as a pure or isolated compound, or as a plant extract in which significant amounts of any THC naturally present has been selectively removed. In another embodiment the phytocannabinoid is CBD.
-
公开(公告)号：US10111840B2
公开(公告)日：2018-10-30
申请号：US14881969
申请日：2015-10-13
申请人： GW Pharma Limited
发明人： Geoffrey Guy , Stephen Wright , Alice Mead , Orrin Devinsky
IPC分类号： A61K31/05 , A61K9/08 , A61K31/352 , A61K45/06 , A61K47/10
摘要： The present disclosure relates to the use of cannabidiol (CBD) for the treatment of atonic seizures. In particular the CBD appears particularly effective in reducing atonic seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; Doose Syndrome; Aicardi syndrome; CDKL5 and Dup15q in comparison to other seizure types. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
-
-
-
-
-
-
-
-
-
搜索结果
48 条记录 (耗时 0.019 秒)
